Compare Eli Lilly And Co (LLY) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Star Bulk Carriers Corp — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while Star Bulk Carriers Corp trades at $29.63 (market cap $3.54B). The key difference: Eli Lilly And Co is far larger — about 293.8× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.17%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Star Bulk Carriers Corp for 24 Days on average.
| LLY | SBLK | |
|---|---|---|
Market Cap | $1.04T | $3.54B |
Volume | 3,064,878 | 1,437,622 |
Sector | Health | Industrials |
52-Week High | $1.28K | $32.49 |
52-Week Low | $799.57 | $16.79 |
Typical Hold Time | 93 Days | 24 Days |
Enterprise Value | $1.09T | $4.22B |
Dividend Yield | 0.59% | 6.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Star Bulk Carriers (SBLK) trades at $29.75, up 0.2% today, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals, with Q2 2026 EPS of $1.21 beating estimates by 27% and a 45% year-over-year revenue surge. A $0.90 dividend for H2 2026 reflects robust free cash flow generation. Analyst consensus is strongly positive, with 14 buys out of 24 ratings, supported by recent insider buying activity.
The outlook for SBLK remains favorable due to consistent earnings beats, attractive valuation multiples, and management's commitment to returning capital. Key risks include shipping rate volatility and broader economic sensitivity. The stock presents a compelling opportunity for value and income investors, though exposure to cyclical industry trends warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
